HALO Stock Analysis: Buy, Sell, or Hold?
HALO - Halozyme Therapeutics, Inc.
$76.10
-0.11 (-0.14%)
▼
5d:
-5.8%
30d:
+7.94%
90d:
+12.2%
HOLD
LOW Confidence
Analysis Updated: Jul 10, 2026 12:00 AM ET
Earnings: Aug 04, 2026
21d
Get Alerted When HALO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: HALO is fairly valued with market pricing in 0.5% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: HALO is fairly valued with market pricing in 0.5% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$135.97
Based on 12.8% avg growth
INTRINSIC VALUE TODAY
$84.42
9.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HALO is currently trading at $76.09, which is considered fair relative to its 30-day fair value range of $69.55 to $77.87. The stock's valuation (Forward PE: 7.7) is in line with its historical norms (7.6). At these levels, the market is pricing in 0.5% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, HALO is in a strong uptrend. Immediate support is located at $72.71, while resistance sits at $82.26.
Market Sentiment: HALO has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $83.90 (+10.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HALO is in a strong uptrend. Immediate support is located at $72.71, while resistance sits at $82.26.
Market Sentiment: HALO has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $83.90 (+10.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$69.55 -
$77.87
Company Quality Score
60/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
81.9%
Protect Your Profits
Holding HALO? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($83.90)
- NEUTRAL: Market pricing in 0.5% annual earnings growth - fairly valued
- CAUTION: Recommendation downgraded due to -5.8% 5-day decline
Trading Range Analysis
30-Day Trading Range
$69.55 -
$77.87
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$72.71
Resistance Level
$82.26
Current Trend
Strong Uptrend
Technical data as of
Jul 10, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.70
Wall Street Target
$83.90
(+10.1%)
Revenue Growth (YoY)
42.2%
Earnings Growth (YoY)
31.2%
Profit Margin
23.1%
Valuation Premium vs History
+0.5% premium
PE vs Historical
7.7 vs 7.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.5%
(market-implied from PE analysis)
1-Year Target
$76.58
(+1%)
2-Year Target
$76.96
(+1%)
3-Year Target
$77.35
(+2%)
3-Yr Target (if PE normalizes)
(PE: 8→8)
PE COMPRESSION
$76.32
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 21.5%)
$386.61
(+407%)
Base:
(SPY PE: 7.7, Growth: 21.5%)
$136.73
(+79%)
Bear:
(PE: 6.5, Growth: 21.5%)
$116.22
(+53%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (28x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 27.59 | Current EPS (TTM): $2.85
Bull Case
$172.96
(+127%)
Analyst growth 100.0%, PE expands to 30.3
Base Case
$157.24
(+106%)
Market implied 100.0%, PE stable at 27.6
Bear Case
$53.46
(-30%)
Severe decline -20.0%, PE contracts to 23.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 13, 2026 12:43 PM ET
Data refreshes hourly during market hours. Next update: 1:43 PM
Data refreshes hourly during market hours. Next update: 1:43 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HALO showing a specific setup today?
Insider Activity (6 Months)
1
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Helen Torley
SELL
10000 shares
2026-04-06
Helen Torley
SELL
20000 shares
2026-04-02
Cortney Caudill
SELL
8857 shares
2026-03-10
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$26 | 55 HOLD |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$822 | 64 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 57 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 62 BUY |
Advanced HALO Option Strategies
Professional options setups generated by AI based on today's HALO price and gamma walls.
